Table 4.
Percentages recalling specific genetic test results correctly by disclosure method and time point, adjusted for APOE genotype.
| Information | In-Person (n=132) |
Telephone (n=125) |
Difference (99% CI) |
|---|---|---|---|
| 1 Year | |||
| Number of risk alleles | 80.5% | 79.8% | −0.7% (−13.5% to 12.2%) |
| Presence/absence of a risk allele | 81.9% | 83.8% | 1.9% (−10.2% to 14.0%) |
| Genotype | 59.3% | 65.0% | 5.7% (−9.9% to 21.2%) |
| Lifetime AD risk estimate (±5%) | 66.4% | 82.2% | 15.8% (2.1% to 29.6%) |
| Remaining AD risk estimate (±5%) | 71.6% | 83.6% | 12.0% (−1.2% to 25.3%) |
| Additional disease association* | 78.1% | 87.3% | 9.2% (−8.5% to 26.8%) |
| 6 Months | |||
| Number of risk alleles | 85.8% | 83.8% | −2.0% (−13.5% to 9.6%) |
| Presence/absence of a risk allele | 86.8% | 85.6% | −1.2% (−12.3% to 9.9%) |
| Genotype | 61.4% | 66.0% | 4.6% (−10.8% to 20.1%) |
| Lifetime AD risk estimate (±5%) | 69.1% | 86.7% | 17.6% (4.6% to 30.6%) |
| Remaining AD risk estimate (±5%) | 77.0% | 80.3% | 3.3% (−9.9% to 16.4%) |
| Additional disease association* | 84.4% | 87.3% | 2.9% (−13.6% to 19.4%) |
| 6 Weeks | |||
| Number of risk alleles | 86.9% | 82.4% | −4.5% (−16.0% to 7.1%) |
| Presence/absence of a risk allele | 90.3% | 86.4% | −3.9% (−14.2% to 6.4%) |
| Genotype | 70.9% | 79.2% | 8.3% (−5.5% to 22.2%) |
| Lifetime AD risk estimate (±5%) | 82.9% | 86.0% | 3.2% (−8.5% to 14.8%) |
| Remaining AD risk estimate (±5%) | 86.3% | 91.9% | 5.6% (−4.3% to 15.6%) |
| Additional disease association* | 78.1% | 83.6% | 5.5% (−13.0% to 24.0%) |
*
Item was administered to participants randomized to AD+CAD disclosure, only.